Black Patients With Merkel Cell Carcinoma Experience Treatment Delays
Factors associated with delays in treatment for patients with Merkel cell carcinoma were investigated.
Merkel Cell Carcinoma
Immunotherapy Is a Viable Treatment Strategy for Advanced MCC and CSCC
The frequent and durable responses to PD-1/PD-L1–blocking antibodies confirm the importance of immune mechanisms in nonmelanoma skin cancer pathogenesis.
Should Predictive Markers, Adjuvant Therapies Be Focus for Merkel Cell Carcinoma Treatment?
Although there are a number of treatments for Merkel cell carcinoma, none offers impressive results. Research directed toward finding predictive markers for response, and adjuvant therapies, are warranted.
Tumor Control Durable With Pembrolizumab in Merkel Cell Cancer
For patients with advanced Merkel cell carcinoma (aMCC), pembrolizumab is associated with durable tumor control and favorable overall survival.
Keytruda Gains Merkel Cell Carcinoma Indication
The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Keytruda Gets Priority Review for Merkel Cell Carcinoma Indication
Merkel cell carcinoma is a rare form of skin cancer associated with higher mortality rates than other skin cancers.
Case Report: Unusual Combined Merkel, Squamous Cell Carcinoma in Situ
Investigators report a rare case of combined Merkel cell and squamous cell carcinoma confined almost exclusively to the epidermis.
Accelerated FDA Approval Granted for Metastatic Merkel Cell Carcinoma
Approval of avelumab for the treatment of patients 12 years and older with Merkel cell carcinoma was granted by the FDA.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...